Vitamins & Nutrition · LP-170
Pyridoxine (Vitamin B6) Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-170Vitamins & Nutrition
- Generic identity
- Pyridoxine (Vitamin B6)Tablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-170
- Generic ingredient
- Pyridoxine (Vitamin B6)
- Dosage form
- Tablet
- Proposed strength
- 25 mg; 50 mg
- Proposed pack
- Blister/bottle
- Portfolio category
- Vitamins & Nutrition
About Pyridoxine (Vitamin B6)
Pyridoxine is a form of vitamin B6, which participates in many enzyme reactions, including aspects of amino-acid metabolism and nervous-system function. Supplementation has specific roles when a deficiency or medicine-related need is identified. A vitamin label should not imply that prolonged higher exposure is harmless. This entry describes an oral ingredient family and does not claim benefits for nonspecific symptoms or general enhancement.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical review considers dietary intake, malabsorption, other supplements and medicines that influence vitamin B6 needs. Certain treatment programmes use pyridoxine for defined preventive purposes, but the indication and product must be verified. Unexplained sensory symptoms, anaemia or fatigue require diagnosis rather than automatic supplementation. The catalogue lists tablet strengths only and does not establish a duration of use, paediatric suitability or a local medicinal versus supplement classification.
Important safety considerations
Excessive or prolonged vitamin B6 exposure can itself cause sensory neuropathy, making total intake from multiple products important. Numbness, tingling or balance changes require assessment. Review kidney disease and interacting medicines, including relevant antiseizure therapies and levodopa formulations. Gastrointestinal effects and sensitivity reactions can occur. Avoid presenting pyridoxine as universally protective against nerve damage; suitability depends on the clinical setting and exposure.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source lists tablets but does not establish salt identity, coating or excipients. The verified vitamin B6 basis of the declared amount and any suitability for splitting require product-level confirmation. Combination supplements are outside this single-ingredient entry.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review the actual indication, all sources of vitamin B6, sensory symptoms and interactions. Confirm local labeling and an appropriate review point for ongoing supplementation.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Pyridoxine (Vitamin B6)
- Dosage form / presentation
- Tablet
- Catalogue strength
- 25 mg; 50 mg
- Catalogue pack
- Blister/bottle
- Portfolio category
- Vitamins & Nutrition
Layer 02
Unresolved product-specific fields
- The catalogue lists pyridoxine tablets at 25 mg and 50 mg but does not identify a salt form, tablet coating, scoring, excipients or suitability for splitting.
- Combination vitamin products are outside this single-ingredient record and are not inferred from generic vitamin B6 context.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NIH ODS: Vitamin B6 — Health Professional Fact Sheetgovernment scientific fact sheet
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-170, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-170.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.